¼¼°èÀÇ Áý´Ü°Ç°­°ü¸® ½ÃÀå
Population Health Management
»óǰÄÚµå : 1594911
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 89 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,163,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,489,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Áý´Ü°Ç°­°ü¸® ½ÃÀåÀº 2030³â±îÁö 893¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 400¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Áý´Ü°Ç°­°ü¸® ½ÃÀåÀº 2023-2030³â CAGR 12.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 893¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¼ÒÇÁÆ®¿þ¾î ÄÄÆ÷³ÍÆ®´Â CAGR 13.1%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 617¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼­ºñ½º ÄÄÆ÷³ÍÆ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 10.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 104¾ï ´Þ·¯, Áß±¹Àº CAGR 16.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Áý´Ü°Ç°­°ü¸® ½ÃÀåÀº 2023³â¿¡ 104¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 220¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³âÀÇ CAGRÀº 16.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 8.1%¿Í 10.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Áý´Ü°Ç°­°ü¸®(PHM) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Áý´Ü°Ç°­°ü¸®(PHM)¶õ ¹«¾ùÀ̸ç, ¿Ö Çö´ë ÇコÄɾ¼­ Áß¿äÇѰ¡?

Áý´Ü°Ç°­°ü¸®(PHM)´Â °Ç°­ ÁöÇ¥¸¦ ´ë±Ô¸ð·Î ¸ð´ÏÅ͸µÇÏ°í ´ëÀÀÇÔÀ¸·Î½á Áý´ÜÀÇ °Ç°­ °á°ú¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ÇコÄɾîÀÇ Àü·«Àû Á¢±Ù ¹æ½ÄÀ¸·Î, ´Ù¾çÇÑ Áý´ÜÀÇ °Ç°­ °ü·Ã µ¥ÀÌÅ͸¦ ¼öÁý ¹× ºÐ¼®ÇÏ¿© ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¹× Á¶Á÷ÀÌ º¸´Ù È¿°úÀûÀÎ °³ÀÔÀ» °èȹÇϰí ȯÀÚ °á°ú¸¦ °³¼±ÇÏ°í ºñ¿ëÀ» Àý°¨ÇÏ¸ç ¸¸¼ºÁúȯÀ» º¸´Ù È¿À²ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í Á¶Á÷ÀÌ º¸´Ù È¿°úÀûÀÎ °³ÀÔÀ» ÅëÇØ ȯÀÚ °á°ú¸¦ °³¼±Çϰí, ºñ¿ëÀ» Àý°¨Çϸç, ¸¸¼ºÁúȯÀ» º¸´Ù È¿À²ÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. PHMÀº ¿¹¹æÀû Ä¡·á, Á¶±â °³ÀÔ, Çù·ÂÀû Ä¡·á¿¡ ÁßÁ¡À» µÒÀ¸·Î½á ÀÇ·á ½Ã½ºÅÛÀ» Áúº´ ±â¹ÝÀÇ ¼Ò±ØÀû ¸ðµ¨¿¡¼­ °Ç°­ ±â¹ÝÀÇ Àû±ØÀû ¸ðµ¨·Î ÀüȯÇϰíÀÚ ÇÕ´Ï´Ù.

PHMÀÇ Áß¿äÇÑ ÄÄÆ÷³ÍÆ® Áß Çϳª´Â ÀüÀڰǰ­±â·Ï(EHR), û±¸ µ¥ÀÌÅÍ, ÀÓ»ó ºÐ¼®, ȯÀÚ º¸°í Á¤º¸ µî ´Ù¾çÇÑ ÃâóÀÇ µ¥ÀÌÅ͸¦ ÅëÇÕÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â Àα¸ÀÇ °Ç°­ Ãß¼¼¸¦ Æò°¡Çϰí, À§Çè¿¡ óÇÑ °³ÀÎÀ» ½Äº°Çϰí, ¸ÂÃã Ä¡·á °èȹÀ» ½ÇÇàÇÏ´Â µ¥ »ç¿ëµÇ¸ç, PHM ½Ã½ºÅÛÀº ƯÈ÷ ¸¸¼ºÁúȯÀ̳ª °íÀ§Çè ¿äÀÎÀ» °¡Áø ȯÀÚ°¡ ¿©·¯ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ·ÎºÎÅÍ ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï Ä¡·á Á¶Á¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÌ Á¢±Ù ¹æ½ÄÀº ȯÀÚ Âü¿©¸¦ Çâ»ó½Ã۰í, Ä¡·á °á°ú¸¦ °³¼±Çϸç, ºÒÇÊ¿äÇÑ ÀçÀÔ¿ø°ú ÀÀ±Þ½Ç ¹æ¹®À» ÁÙÀ̱â À§ÇØ °í¾ÈµÇ¾ú½À´Ï´Ù.

PHM ÇÁ·Î±×·¥Àº °³º° ȯÀÚ Ä¡·á¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¿¹¹æ Á¶Ä¡¿¡ ÃÊÁ¡À» ¸ÂÃß¾î ¿¹¹æ °¡´ÉÇÑ Áúº´ÀÇ ¹ß»ýÀ» ÁÙÀÌ°í ¸¸¼ºÁúȯÀ» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®ÇÔÀ¸·Î½á Á¶Á÷ÀÌ ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Á¤ºÎ, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ, º¸Çè»ç, °í¿ëÁÖ´Â ±ÞÁõÇÏ´Â ÀÇ·á ºñ¿ë¿¡ ´ëÀÀÇϰí, ȯÀÚ ¸¸Á·µµ¸¦ ³ôÀ̰í, °í·ÉÈ­ ¹× º¹ÀâÇÑ °Ç°­ »óŸ¦ °¡Áø »ç¶÷µéÀÇ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇÑ Àü·«ÀÇ ÀÏȯÀ¸·Î PHMÀÇ Ã¤ÅÃÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Áý´Ü°Ç°­°ü¸® ½ÃÀåÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

ºòµ¥ÀÌÅÍ ºÐ¼®, ÀΰøÁö´É(AI), ¿ø°ÝÀÇ·á ¹× ¿þ¾î·¯ºí ±â¼úÀÇ Çõ½ÅÀ¸·Î ÀÎÇØ Áý´Ü °Ç°­ µ¥ÀÌÅ͸¦ ¼öÁý, ºÐ¼® ¹× Ȱ¿ëÇÏ´Â ¹æ½ÄÀÌ º¯È­Çϰí ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ µ¿Çâ Áß Çϳª´Â ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» PHM Ç÷§Æû¿¡ ÅëÇÕÇÏ´Â °ÍÀ¸·Î, AI ¾Ë°í¸®ÁòÀº ´Ù¾çÇÑ ÃâóÀÇ ¹æ´ëÇÑ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ °íÀ§Ç豺À» º¸´Ù È¿°úÀûÀ¸·Î ½Äº°Çϰí, °Ç°­ °á°ú¸¦ ¿¹ÃøÇϰí, Ä¡·á °èȹÀ» °³ÀÎÈ­ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¿¹Ãø ºÐ¼®Àº ÀÔ¿ø À§Çè¿¡ óÇÑ È¯ÀÚ¿¡°Ô Ç÷¡±×¸¦ Ç¥½ÃÇÒ ¼ö ÀÖÀ¸¸ç, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Ç¥ÀûÈ­µÈ Ä¡·á °èȹÀ¸·Î Á¶±â¿¡ °³ÀÔÇÏ¿© ºñ¿ëÀÌ ¸¹ÀÌ µå´Â ÀÔ¿øÀ» ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù.

Ŭ¶ó¿ìµå ±â¹Ý PHM Ç÷§ÆûÀÇ ºÎ»óµµ Å« È帧À¸·Î, µ¥ÀÌÅÍ ÀúÀå, ¾×¼¼½º ¹× ºÐ¼®À» º¸´Ù È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÏ°Ô ¸¸µé¾îÁÖ°í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ½Ã½ºÅÛÀ» ÅëÇØ ÀÇ·á ±â°üÀº EHR, ¿þ¾î·¯ºí ±â±â, û±¸ µ¥ÀÌÅÍ µî ¿©·¯ ¼Ò½ºÀÇ È¯ÀÚ µ¥ÀÌÅ͸¦ Áß¾Ó ÁýÁßÈ­Çϰí ÅëÇÕÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®À» Á¦°øÇÏ°í ¿©·¯ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ µ¿ÀÏÇÑ È¯ÀÚ µ¥ÀÌÅÍ¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á ´õ ³ªÀº Áø·á Á¶Á¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀº ¿ø°ÝÀÇ·á ¼­ºñ½ºµµ Áö¿øÇÏ¿© ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ȯÀÚÀÇ °Ç°­ µ¥ÀÌÅ͸¦ ¾ÈÀüÇÏ°Ô °ü¸®Çϸ鼭 ¿ø°ÝÁö, ƯÈ÷ ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª°ú ³óÃÌ Áö¿ªÀÇ È¯ÀÚ¿¡°Ô Á¢±Ù ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

¿ø°ÝÀÇ·á ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ±â¼úÀº PHM ÇÁ·Î±×·¥¿¡ Á¡Á¡ ´õ ÇʼöÀûÀÎ ¿ä¼Ò°¡ µÇ°í ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ¿ø°ÝÀÇ·áÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, PHM ½Ã½ºÅÛÀº ¿ø°ÝÀÇ·á ¼Ö·ç¼ÇÀ» ÅëÇÕÇÏ¿© ÀÇ·á ½Ã¼³À» ¹æ¹®ÇÏÁö ¸øÇϴ ȯÀÚµéÀ» µ¹º¸°í ÀÖ½À´Ï´Ù. ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ¹× ½º¸¶Æ® ¼¾¼­¿Í °°Àº ¿ø°Ý ¸ð´ÏÅ͸µ ±â±â¸¦ ÅëÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ȯÀÚÀÇ È°·Â ¡ÈÄ, ¾à¹° ¼øÀÀµµ ¹× ½Åü Ȱµ¿À» ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¼ÓÀûÀÎ µ¥ÀÌÅÍ È帧Àº ÀÓ»óÀǰ¡ ´ç´¢º´, °íÇ÷¾Ð°ú °°Àº ¸¸¼ºÁúȯÀ» ¸ð´ÏÅ͸µÇϰí ÇÊ¿äÇÑ °æ¿ì °³ÀÔÇÏ´Â µ¥ µµ¿òÀÌ µÇ¾î º´¿ø ÀçÀÔ¿ø°ú ÀÀ±Þ½Ç ¹æ¹®À» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ¹ßÀüÀº µ¥ÀÌÅÍ º¸¾È°ú »óÈ£ ¿î¿ë¼ºÀ» Çâ»ó½Ã۱â À§ÇØ PHM¿¡ ºí·ÏüÀÎ ±â¼úÀ» »ç¿ëÇÏ´Â °ÍÀÔ´Ï´Ù. ºí·Ï üÀÎÀº ȯÀÚ µ¥ÀÌÅÍÀÇ ¾ÈÀüÇÏ°í ºÐ»êµÈ ÀúÀåÀ» °¡´ÉÇϰÔÇÏ¿© ÇÁ¶óÀ̹ö½Ã¸¦ º¸ÀåÇÏ´Â µ¿½Ã¿¡ ÀÇ·á ³×Æ®¿öÅ© °£ÀÇ ¿øÈ°ÇÑ µ¥ÀÌÅÍ °øÀ¯¸¦ °¡´ÉÇϰÔÇϸç, ÀÌ´Â PHM ÇÁ·Î±×·¥ÀÌ º´¿ø, º¸Çè ȸ»ç, ȯÀÚ ÀڽŠµî ´Ù¾çÇÑ ÃâóÀÇ µ¥ÀÌÅÍ ÅëÇÕ¿¡ Å©°Ô ÀÇÁ¸ÇϹǷΠƯÈ÷ Áß¿äÇÕ´Ï´Ù. ÀÇÁ¸Çϰí ÀÖÀ¸¹Ç·Î À̴ ƯÈ÷ Áß¿äÇÕ´Ï´Ù.

¶ÇÇÑ È¯ÀÚ Âü¿© ±â¼úÀº PHM¿¡¼­ Çʼö ºÒ°¡°áÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ °Ç°­(mHealth) ¾Û, ȯÀÚ Æ÷ÅÐ ¹× µðÁöÅÐ ÅøÀº °³ÀÎÀÌ ÀÚ½ÅÀÇ ÇコÄɾ º¸´Ù Àû±ØÀûÀÎ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀ» ÅëÇØ ȯÀÚ´Â ÀÚ½ÅÀÇ °Ç°­ µ¥ÀÌÅÍ¿¡ ¾×¼¼½ºÇϰí, ¾àÀ» ÃßÀûÇϰí, ¿¹¾àÇϰí, ÀÇ·áÁø°ú ¼ÒÅëÇÒ ¼ö ÀÖÀ¸¸ç, ´õ ³ªÀº Âü¿©¿Í Ä¡·á °èȹ Áؼö¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚ Âü¿©µµ Çâ»óÀº PHM ÇÁ·Î±×·¥ÀÇ ÇÙ½É ¸ñÇ¥ÀÎ °Ç°­ °á°ú °³¼±À¸·Î À̾îÁý´Ï´Ù.

Áý´Ü°Ç°­°ü¸®ÀÇ ÁÖ¿ä ¿ëµµ ¹× ÃÖÁ¾ »ç¿ë ºÐ¾ß´Â ¹«¾ùÀΰ¡?

Áý´Ü°Ç°­°ü¸®´Â ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ, º¸Çè»ç, Á¤ºÎ ±â°ü, °í¿ëÁÖ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ Æø³Ð°Ô Ȱ¿ëµÇ°í ÀÖÀ¸¸ç, °¢ ºÐ¾ß´Â PHM ½Ã½ºÅÛÀ» Ȱ¿ëÇÏ¿© ȯÀÚ °ü¸® °³¼±°ú ºñ¿ë Àý°¨À» ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ºÐ¾ß¿¡¼­´Â º´¿ø, Ŭ¸®´Ð, ÀÇ»ç ³×Æ®¿öÅ©°¡ ȯÀÚ Áý´ÜÀ» º¸´Ù È¿À²ÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ PHMÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» ÅëÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ¸¸¼ºÁúȯÀ» ¸ð´ÏÅ͸µÇϰí, À§Çè¿¡ óÇÑ È¯ÀÚ¸¦ ½Äº°Çϰí, Áúº´ ÁøÇàÀ» ¿¹¹æÇÏ´Â ¸ÂÃãÇü Ä¡·á °èȹÀ» Á¦°øÇÒ ¼ö ÀÖÀ¸¸ç, PHM ÇÁ·Î±×·¥Àº ´ç´¢º´, ½ÉÀ庴, õ½Ä µî Áö¼ÓÀûÀÎ Ä¡·á Á¶Á¤ ¹× ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ ¸¸¼ºÁúȯ ȯÀÚ¸¦ °ü¸®ÇÏ´Â µ¥ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ƯÈ÷ Áß¿äÇÕ´Ï´Ù.

ÁöºÒÀںι®(º¸Çè»ç)µµ PHM ÇÁ·Î±×·¥ÀÇ ÁÖ¿ä »ç¿ëÀÚÀÔ´Ï´Ù. º¸Çè»ç´Â PHMÀ» ÅëÇØ ÀÇ·áºñ °ü¸®, ºÒÇÊ¿äÇÑ ÀÇ·áºñ Àý°¨, ȯÀÚ °á°ú °³¼±À» À§ÇØ PHMÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. º¸Çè»ç´Â û±¸ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© ¸¸¼ºÁúȯ ºñÀ² Áõ°¡¿Í °°Àº ȯÀÚ °Ç°­ Ãß¼¼¸¦ ÆÄ¾ÇÇÏ¿© À£´Ï½º ÇÁ·Î±×·¥ ¹× ¿¹¹æ ÀÇ·á ±¸»óÀ» ½ÃÇàÇÒ ¼ö ÀÖÀ¸¸ç, PHM ½Ã½ºÅÛÀº ȯÀÚ°¡ º´¿¡ °É·ÈÀ» ¶§ Ä¡·áÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó °Ç°­ »óŸ¦ À¯ÁöÇÔÀ¸·Î½á ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô º¸»óÀ» Á¦°øÇÏ´Â °¡Ä¡ ±â¹Ý ÀÇ·á ½Ã½ºÅÛÀÔ´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô º¸»óÀ» Á¦°øÇÏ´Â °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨À» ¼³°èÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ¼­ºñ½º´ç ºñ¿ë¿¡¼­ °¡Ä¡ ±â¹Ý Áø·á·ÎÀÇ ÀüȯÀº ȯÀÚ °á°ú¸¦ °³¼±Çϸ鼭 ºñ¿ëÀ» Àý°¨ÇϰíÀÚ ÇÏ´Â º¸Çè»çµé¿¡°Ô Á¡Á¡ ´õ ÇÙ½ÉÀûÀÎ Àü·«ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Á¤ºÎ º¸°Ç ±â°ü ¹× °ø°ø º¸°Ç ±â°üÀº PHM ÇÁ·Î±×·¥À» Ȱ¿ëÇÏ¿© °øÁß º¸°Ç µ¿ÇâÀ» ¸ð´ÏÅ͸µÇϰí, Áúº´ ¹ß»ýÀ» °ü¸®Çϰí, Áý´Ü °Ç°­ ±¸»óÀ» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î COVID-19 ÆÒµ¥¹Í ±â°£ Áß Á¤ºÎ´Â PHM ½Ã½ºÅÛÀ» »ç¿ëÇÏ¿© °¨¿°·üÀ» ÃßÀûÇÏ°í °íÀ§Ç豺À» ½Äº°ÇÏ°í ¹é½Å Á¢Á¾ Ä·ÆäÀÎÀ» ½Ç½ÃÇß½À´Ï´Ù. °øÁß º¸°Ç ±â°üÀº PHMÀ» ÅëÇØ ±ú²ýÇÑ ¹°, ¿µ¾ç°¡ ÀÖ´Â ½Äǰ, ÀÇ·á ¼­ºñ½º Á¢±Ù¼º µî °Ç°­ÀÇ »çȸÀû °áÁ¤ ¿äÀÎÀ» ¸ñÇ¥·Î ÇÏ´Â ÇÁ·Î±×·¥À» ¼³°èÇÏ¿© ´Ù¾çÇÑ Áý´ÜÀÇ °Ç°­ ÇüÆò¼ºÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.

°í¿ëÁÖ¿Í ±â¾÷ÀÇ À£´Ï½º ÇÁ·Î±×·¥µµ PHM ½Ã½ºÅÛÀ» Ȱ¿ëÇÏ¿© Á÷¿øÀÇ °Ç°­À» ¸ð´ÏÅ͸µÇÏ°í °á±ÙÀ» ÁÙÀÌ¸ç »ý»ê¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Á÷¿øÀÇ °Ç°­ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÔÀ¸·Î½á ±â¾÷Àº °Ç°­ÇÑ ÇൿÀ» Àå·ÁÇÏ°í ¸¸¼ºÁúȯÀ» ¿¹¹æÇϸç Á÷¿ø ÀüüÀÇ °Ç°­À» °³¼±ÇÏ´Â À£ºù ±¸»óÀ» ±¸ÇöÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ±â¾÷Àº PHM ÅøÀ» ÅëÇØ ÆÄ¾ÇµÈ Á÷¿øµéÀÇ ´ÏÁ ±â¹ÝÀ¸·Î ÇÇÆ®´Ï½º ÇÁ·Î±×·¥, Á¤½Å°Ç°­ Áö¿ø, ±Ý¿¬ ÇÁ·Î±×·¥ µîÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·Î±×·¥Àº Á÷¿øÀÇ À£ºùÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó °í¿ëÁÖÀÇ ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÏ°í ´õ °Ç°­ÇÏ°í »ý»êÀûÀÎ ÀηÂÀ» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦¾à-»ý¸í°úÇÐ »ê¾÷µµ PHMÀ» µµÀÔÇÏ¿© Áý´Ü °Ç°­ µ¿ÇâÀ» ÆÄ¾ÇÇÏ°í Æ¯Á¤ ±×·ìÀ» ´ë»óÀ¸·Î ÇÑ Ä¡·á¹ýÀ» ¼³°èÇϰí ÀÖ½À´Ï´Ù. Áý´Ü µ¥ÀÌÅ͸¦ ºÐ¼®ÇÔÀ¸·Î½á Á¦¾àȸ»ç´Â Áúº´ÀÇ À¯º´·üÀ» ´õ Àß ÀÌÇØÇÏ°í Æ¯Á¤ Áý´ÜÀÇ ¿ä±¸¸¦ ÃæÁ·½ÃŰ´Â ÀǾàǰ°ú Ä¡·á °èȹÀ» °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù.¶Ç ´Ù¸¥ ÇýÅÃÀ¸·Î, ÀÓ»ó½ÃÇèÀº PHM µ¥ÀÌÅ͸¦ ÅëÇØ °Ç°­ ÁöÇ¥¸¦ ±â¹ÝÀ¸·Î ÇÑ º¸´Ù Á¤È®ÇÑ ÇÇÇèÀÚ ¼±ÅÃÀÌ °¡´ÉÇØÁ® ´õ ³ªÀº °á°ú¿Í ´õ È¿À²ÀûÀÎ ½ÃÇèÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

Áý´Ü°Ç°­°ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Áý´Ü°Ç°­°ü¸® ½ÃÀåÀÇ ¼ºÀå¿¡´Â ¸¸¼ºÁúȯÀÇ È®»ê, ÀÇ·áºñ Áõ°¡, °Ç°­ µ¥ÀÌÅÍ ºÐ¼®ÀÇ ¹ßÀü, °¡Ä¡ ±â¹Ý ÀǷḦ Àå·ÁÇÏ´Â Á¤ºÎÀÇ ±¸»ó µî ¿©·¯ °¡Áö ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. °¡Àå Å« ¼ºÀå ¿äÀÎ Áß Çϳª´Â ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ºñ¸¸°ú °°Àº ¸¸¼ºÁúȯÀÌ Àü ¼¼°è¿¡¼­ Áõ°¡Çϸ鼭 ÀÇ·á ½Ã½ºÅÛ¿¡ Å« ºÎ´ãÀ» ÁÖ°í ÀÖ´Â °Í. PHM ÇÁ·Î±×·¥Àº Á¶±â °³ÀÔ, ¿¬°è Áø·á, ȯÀÚ Âü¿©¿¡ ÃÊÁ¡À» ¸ÂÃß¾î ÀÌ·¯ÇÑ ¸¸¼ºÁúȯÀ» °ü¸®ÇÏ°í ±Ã±ØÀûÀ¸·Î ÀÔ¿ø ¹× ÀÀ±Þ½Ç ¹æ¹®À» ÁÙÀ̱â À§ÇØ °í¾ÈµÈ ÇÁ·Î±×·¥ÀÔ´Ï´Ù. ÀÔ¿ø ¹× ÀÀ±Þ½Ç ¹æ¹®À» ÁÙÀ̱â À§ÇØ °í¾ÈµÈ ÇÁ·Î±×·¥ÀÔ´Ï´Ù.

°¡Ä¡ ±â¹Ý Áø·á·ÎÀÇ Àüȯµµ PHM ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ ¼­ºñ½º Á¦°ø·®¿¡ µû¶ó º¸»óÀ» ¹Þ´Â ¼­ºñ½º´ç ºñ¿ë ¸ðµ¨¿¡¼­ ȯÀÚÀÇ °á°ú¸¦ Áß½ÃÇÏ´Â °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨·Î ÀüȯÇÔ¿¡ µû¶ó PHM ½Ã½ºÅÛÀÇ Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. °¡Ä¡ ±â¹Ý Áø·á´Â ȯÀÚ Áý´Ü, °Ç°­ µ¿Çâ, Áø·á Á¦°ø ÁöÇ¥¿¡ ´ëÇÑ ±íÀº ÀÌÇØ°¡ ÇÊ¿äÇϸç, ÀÌ´Â PHM ÇÁ·Î±×·¥À» ÅëÇØ ÃËÁøµÉ ¼ö ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ Ä¡·áÀÇ °ÝÂ÷¸¦ ÆÄ¾ÇÇϰí Á¶±â¿¡ °³ÀÔÇÔÀ¸·Î½á ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ºñ¿ëÀ» Àý°¨ÇÏ°í °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â °¡Ä¡ ±â¹Ý Ä¡·áÀÇ ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â °ÍÀÔ´Ï´Ù.

Á¤ºÎ Â÷¿øÀÇ ³ë·Â°ú ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©µµ PHM ÇÁ·Î±×·¥ µµÀÔ¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ACA(Affordable Care Act)¿Í MedicareÀÇ ACO(Accountable Care Organization) ¸ðµ¨ÀÌ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô ȯÀÚ °á°ú¸¦ ÃßÀûÇÏ°í ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â PHM ½Ã½ºÅÛÀ» µµÀÔÇÒ ¼ö ÀÖ´Â Àμ¾Æ¼ºê¸¦ Á¦°øÇÕ´Ï´Ù. À¯·´°ú ¾Æ½Ã¾Æ °¢±¹¿¡¼­µµ ºñ½ÁÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸¸ç, °¢±¹ Á¤ºÎ´Â °í·ÉÈ­¿Í ¸¸¼ºÁúȯÀ» °ü¸®Çϸ鼭 ÀÇ·áÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

ÇコÄÉ¾î µ¥ÀÌÅÍ ºÐ¼®ÀÇ ¹ßÀü°ú ´Ù¾çÇÑ ÃâóÀÇ °Ç°­ µ¥ÀÌÅÍ °¡¿ë¼ºÀÌ È®´ëµÊ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â Áý´ÜÀÇ °Ç°­ »óŸ¦ ´õ Àß ÀÌÇØÇÏ°í °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ºòµ¥ÀÌÅÍ ºÐ¼®, AI, ¸Ó½Å·¯´×À» ÅëÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ȯÀÚ µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ºÐ¼®ÇÏ¿© À§Çè¿¡ óÇÑ °³ÀÎÀ» ½Äº°Çϰí, ¸ÂÃãÇü °³ÀÔÀ» °èȹÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿þ¾î·¯ºí ±â±â, ¸ð¹ÙÀÏ °Ç°­ ¾Û, ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀÇ º¸±ÞÀº º¸´Ù Á¾ÇÕÀûÀΠȯÀÚ ¸ð´ÏÅ͸µÀ» À§ÇØ PHM Ç÷§Æû¿¡ ÅëÇÕÇÒ ¼ö ÀÖ´Â Áö¼ÓÀûÀÎ ½Ç½Ã°£ °Ç°­ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á PHM ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î ¸¹Àº ±¹°¡¿¡¼­ °í·ÉÈ­°¡ ÁøÇàµÇ¸é¼­ PHM ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. PHM ÇÁ·Î±×·¥Àº ȯÀÚ Áß½ÉÀÇ »çÀü ¿¹¹æÀû Ä¡·á¸¦ Á¦°øÇÏ¿© ÀÔ¿øÀ» ÁÙÀÌ°í »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â ȯÀÚ Áß½ÉÀÇ »çÀü ¿¹¹æÀû Ä¡·á¸¦ Á¦°øÇÔÀ¸·Î½á ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ °í·ÉÈ­ Àα¸ÀÇ º¹ÀâÇÑ ¿ä±¸¸¦ °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.

°á·ÐÀûÀ¸·Î, Áý´Ü°Ç°­°ü¸® ½ÃÀåÀº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀü, Á¤ºÎ ±¸»ó, °¡Ä¡ ±â¹Ý Ä¡·á·ÎÀÇ ¼¼°è Àüȯ¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ȯÀÚ °á°ú °³¼±, ÀÇ·áºñ Àý°¨, ¿¹¹æ ÀÇ·á¿¡ ÁßÁ¡À» µÐ PHMÀº Àü ¼¼°è Çö´ë ÀÇ·á ½Ã½ºÅÛÀÇ Ãʼ®ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

ÄÄÆ÷³ÍÆ®(¼ÒÇÁÆ®¿þ¾î, ¼­ºñ½º);µµÀÔ(¿ÂÇÁ·¹¹Ì½º, Ŭ¶ó¿ìµå);ÃÖÁ¾»ç¿ëÀÚ(ÇコÄɾî ÇÁ·Î¹ÙÀÌ´õ, ÇコÄɾî ÁöºÒÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 34°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Population Health Management Market to Reach US$89.3 Billion by 2030

The global market for Population Health Management estimated at US$40.0 Billion in the year 2023, is expected to reach US$89.3 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Software Component, one of the segments analyzed in the report, is expected to record a 13.1% CAGR and reach US$61.7 Billion by the end of the analysis period. Growth in the Services Component segment is estimated at 10.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.4 Billion While China is Forecast to Grow at 16.2% CAGR

The Population Health Management market in the U.S. is estimated at US$10.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$22.0 Billion by the year 2030 trailing a CAGR of 16.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 10.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global Population Health Management (PHM) Market – Key Trends & Drivers Summarized

What Is Population Health Management (PHM) and Why Is It Critical in Modern Healthcare?

Population Health Management (PHM) is a strategic approach in healthcare aimed at improving the health outcomes of a group by monitoring and addressing health indicators on a large scale. PHM involves the collection and analysis of health-related data from various populations, allowing healthcare providers and organizations to design more effective interventions, improve patient outcomes, reduce costs, and manage chronic diseases more efficiently. By focusing on preventative care, early intervention, and coordinated treatment, PHM seeks to shift healthcare systems from reactive, illness-based models to proactive, wellness-oriented models.

One of the key components of PHM is data integration from various sources such as electronic health records (EHRs), claims data, clinical analytics, and patient-reported information. This data is used to assess population health trends, identify at-risk individuals, and implement personalized care plans. PHM systems enable care coordination, ensuring that patients, particularly those with chronic conditions or high-risk factors, receive appropriate care from multiple healthcare providers. This approach is designed to improve patient engagement, enhance care outcomes, and reduce unnecessary hospital readmissions and emergency room visits.

In addition to improving individual patient care, PHM programs help organizations reduce healthcare costs by focusing on preventative measures, reducing the incidence of preventable diseases, and managing chronic conditions more effectively. Governments, healthcare providers, insurers, and employers are increasingly adopting PHM as part of their strategy to address the rising costs of healthcare, improve patient satisfaction, and meet the needs of aging populations and individuals with complex medical conditions.

How Are Technological Advancements Shaping the Population Health Management Market?

Technological advancements are driving significant growth in the PHM market, with innovations in big data analytics, artificial intelligence (AI), telemedicine, and wearable technologies transforming the way population health data is collected, analyzed, and acted upon. One of the most notable trends is the integration of artificial intelligence and machine learning into PHM platforms. AI algorithms can analyze vast amounts of data from different sources, enabling healthcare providers to identify high-risk populations more effectively, predict health outcomes, and personalize care plans. Predictive analytics, for instance, can flag patients at risk of hospitalization, allowing providers to intervene early with targeted care plans and prevent costly hospital admissions.

The rise of cloud-based PHM platforms is another major trend, making data storage, access, and analysis more efficient and scalable. Cloud-based systems enable healthcare organizations to centralize and integrate patient data from multiple sources, including EHRs, wearable devices, and claims data. These platforms offer real-time data analysis and enable better care coordination by allowing multiple healthcare providers to access the same patient data. Cloud computing also supports telehealth services, enabling healthcare providers to reach patients remotely, especially those in underserved or rural areas, while managing their health data securely.

Telemedicine and remote patient monitoring (RPM) technologies are becoming increasingly integral to PHM programs. The COVID-19 pandemic accelerated the adoption of telehealth, and PHM systems have been integrating telemedicine solutions to provide care to patients who are unable to visit healthcare facilities. Remote monitoring devices, such as wearables and smart sensors, allow healthcare providers to track patients’ vital signs, medication adherence, and physical activity in real time. This constant stream of data helps clinicians monitor chronic conditions, such as diabetes and hypertension, and intervene when necessary, reducing hospital readmissions and emergency visits.

Another critical advancement is the use of blockchain technology in PHM to improve data security and interoperability. Blockchain allows for secure, decentralized storage of patient data, ensuring privacy while enabling seamless sharing of data across healthcare networks. This is particularly important as PHM programs rely heavily on the integration of data from different sources, including hospitals, insurance companies, and patients themselves.

Additionally, patient engagement technologies are becoming essential in PHM. Mobile health (mHealth) apps, patient portals, and digital tools empower individuals to take a more active role in managing their health. These tools allow patients to access their health data, track medication, schedule appointments, and communicate with their healthcare providers, fostering better engagement and adherence to treatment plans. Higher patient engagement translates to better health outcomes, which is a core goal of PHM programs.

What Are the Key Applications and End-Use Sectors for Population Health Management?

Population Health Management has broad applications across a variety of sectors, including healthcare providers, insurers, government agencies, and employers, each leveraging PHM systems to improve patient care and reduce costs. In the healthcare provider sector, PHM is used by hospitals, clinics, and physician networks to manage patient populations more efficiently. These systems enable providers to monitor chronic diseases, identify at-risk populations, and deliver personalized care plans that prevent disease progression. PHM programs are particularly critical in managing patients with chronic diseases such as diabetes, heart disease, and asthma, which require ongoing care coordination and monitoring.

The payer sector (insurance companies) is also a major user of PHM programs. Insurers use PHM to manage healthcare costs, reduce unnecessary medical expenses, and improve patient outcomes. By analyzing claims data, insurers can identify trends in patient health, such as rising rates of chronic conditions, and implement wellness programs or preventative care initiatives. PHM systems help payers design value-based care models that reward healthcare providers for keeping patients healthy rather than treating them when they are sick. This shift from fee-for-service to value-based care is increasingly becoming a core strategy for insurers aiming to reduce costs while improving patient outcomes.

Government health agencies and public health organizations utilize PHM programs to monitor public health trends, manage disease outbreaks, and implement population-wide health initiatives. For example, during the COVID-19 pandemic, governments used PHM systems to track infection rates, identify high-risk populations, and implement vaccination campaigns. Public health agencies can use PHM to design programs that target social determinants of health, such as access to clean water, nutritious food, and healthcare services, helping to improve health equity across different population groups.

Employers and corporate wellness programs also use PHM systems to monitor employee health, reduce absenteeism, and improve productivity. By analyzing employee health data, companies can implement wellness initiatives that promote healthy behaviors, prevent chronic diseases, and improve overall workforce health. For example, companies may offer fitness programs, mental health support, or smoking cessation programs based on the needs of their workforce as identified through PHM tools. These programs not only improve employee well-being but also reduce healthcare costs for employers, leading to a healthier and more productive workforce.

The pharmaceutical and life sciences industries are also adopting PHM to identify population health trends and design targeted therapies for specific groups. By analyzing population data, pharmaceutical companies can better understand the prevalence of diseases and develop drugs or treatment plans that meet the needs of specific populations. In addition, clinical trials are benefiting from PHM data by enabling more precise selection of participants based on health indicators, leading to better outcomes and more efficient trials.

What Factors Are Driving Growth in the Population Health Management Market?

Several factors are driving the growth of the population health management market, including the rising prevalence of chronic diseases, increasing healthcare costs, advancements in health data analytics, and government initiatives promoting value-based care. One of the most significant growth drivers is the global rise in chronic diseases, such as diabetes, cardiovascular disease, and obesity, which are placing a tremendous burden on healthcare systems. PHM programs are designed to manage these chronic conditions by focusing on early intervention, coordinated care, and patient engagement, ultimately reducing hospitalizations and emergency visits.

The shift toward value-based care is another major driver of the PHM market. As healthcare systems around the world move away from fee-for-service models, where providers are paid based on the volume of services they deliver, to value-based care models that focus on patient outcomes, PHM systems are becoming increasingly critical. Value-based care requires a deep understanding of patient populations, health trends, and care delivery metrics, all of which are facilitated by PHM programs. By using data analytics to identify gaps in care and intervene early, healthcare providers can improve outcomes while controlling costs, aligning with the goals of value-based care.

Government initiatives and regulatory frameworks are also pushing the adoption of PHM programs. In the United States, the Affordable Care Act (ACA) and Medicare’s Accountable Care Organization (ACO) model incentivize healthcare providers to implement PHM systems that track patient outcomes and reduce costs. Similar initiatives are being rolled out in countries across Europe and Asia, where governments are focusing on improving healthcare quality while managing aging populations and chronic diseases.

Advances in healthcare data analytics and the growing availability of health data from diverse sources are enabling healthcare providers to better understand and manage population health. Big data analytics, AI, and machine learning are allowing providers to analyze patient data in real time, identify at-risk individuals, and design targeted interventions. The proliferation of wearable devices, mobile health apps, and remote monitoring technologies is further driving the growth of the PHM market by providing continuous, real-time health data that can be integrated into PHM platforms for more comprehensive patient monitoring.

Finally, the aging population in many countries is increasing the demand for PHM systems. As the global population ages, the prevalence of chronic diseases and the need for coordinated care for elderly patients is rising. PHM programs can help healthcare providers manage the complex needs of aging populations by providing proactive, patient-centered care that reduces hospitalizations and improves quality of life.

In conclusion, the population health management market is set for robust growth, driven by the rising prevalence of chronic diseases, technological advancements, government initiatives, and the global shift toward value-based care. With its focus on improving patient outcomes, reducing healthcare costs, and promoting preventative care, PHM is becoming a cornerstone of modern healthcare systems worldwide.

SCOPE OF STUDY:

The report analyzes the Population Health Management market in terms of US$ Million by the following Component; Deployment; End-Use, and Geographic Regions/Countries:

Segments:

Component (Software, Services); Deployment (On-Premise, Cloud); End-Use (Healthcare Providers, Healthcare Payers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â